Land: Singapore
Sprog: engelsk
Kilde: HSA (Health Sciences Authority)
RAMIPRIL
SANOFI-AVENTIS SINGAPORE PTE. LTD.
C09AA05
2.5 mg
TABLET
RAMIPRIL 2.5 mg
ORAL
Prescription Only
SANOFI S.r.l.
ACTIVE
1997-12-22
This package insert is continually updated: please read carefully before using a new pack! TRITACE ® 1.25 TABLETS TRITACE ® 2.5 TABLETS TRITACE ® 5 TABLETS TRITACE ® 10 TABLETS _Ramipril _ _ _ [SANOFI LOGO] COMPOSITION Each tablet Tritace ® 1.25 contains, as active ingredient, 1.25 mg ramipril. Each tablet Tritace ® 2.5 contains, as active ingredient, 2.5 mg ramipril. Each tablet Tritace ® 5 contains, as active ingredient, 5 mg ramipril. Each tablet Tritace ® 10 contains, as active ingredient, 10 mg ramipril. Excipients: Methylhydroxypropylcellulose, pregelatinized maize starch, microcrystalline cellulose, sodium stearyl fumarate, yellow ferric oxide (Tritace 2.5 only), red ferric oxide (Tritace 5 only). Not all presentation is available in all countries. PROPERTIES Ramiprilat, the active metabolite of ramipril, is a potent and long-acting angiotensin converting enzyme (ACE) inhibitor. Administration of Tritace results in a vasodilatation and, especially in hypertensive patients, in a reduction of blood pressure. The blood-pressure-lowering effect of a single dose occurs within 1 – 2 hours after intake, reaching its peak within 3 - 6 hours, and usually lasts 24 hours. Tritace is also effective in the treatment of congestive heart failure. Further, in patients demonstrating clinical signs of congestive heart failure after an acute myocardial infarction, Tritace has been shown to decrease the mortality risk (including the risks of sudden death, of progression to severe/resistant heart failure and of failure-related hospitalisation). Tritace, when administered on a preventive basis, significantly reduces the incidence of myocardial infarction, stroke or cardiovascular deaths in patients with an increased cardiovascular risk attributable to vascular diseases (such as manifest coronary heart disease, or a history of stroke or of peripheral vascular disease) or to diabetes mellitus with at l Læs hele dokumentet
SG/TRI/0322/CCDS V16-18 1 This package insert is continually updated: please read carefully before using a new pack! TRITACE ® 2.5 TABLETS TRITACE ® 5 TABLETS _Ramipril _ _ _ COMPOSITION Each tablet Tritace ® 2.5 contains, as active ingredient, 2.5 mg ramipril. Each tablet Tritace ® 5 contains, as active ingredient, 5 mg ramipril. Excipients: Methylhydroxypropylcellulose, pregelatinized maize starch, microcrystalline cellulose, sodium stearyl fumarate, yellow ferric oxide (Tritace 2.5 only), red ferric oxide (Tritace 5 only). Not all presentation is available in all countries. PROPERTIES Ramiprilat, the active metabolite of ramipril, is a potent and long-acting angiotensin converting enzyme (ACE) inhibitor. Administration of Tritace results in a vasodilatation and, especially in hypertensive patients, in a reduction of blood pressure. The blood-pressure-lowering effect of a single dose occurs within 1 – 2 hours after intake, reaching its peak within 3 - 6 hours, and usually lasts 24 hours. Tritace is also effective in the treatment of congestive heart failure. Further, in patients demonstrating clinical signs of congestive heart failure after an acute myocardial infarction, Tritace has been shown to decrease the mortality risk (including the risks of sudden death, of progression to severe/resistant heart failure and of failure-related hospitalisation). Tritace, when administered on a preventive basis, significantly reduces the incidence of myocardial infarction, stroke or cardiovascular deaths in patients with an increased cardiovascular risk attributable to vascular diseases (such as manifest coronary heart disease, or a history of stroke or of peripheral vascular disease) or to diabetes mellitus with at least one additional risk factor (microalbuminuria, hypertension, elevated total cholesterol levels, low high-density lipoprotein cholesterol levels, smoking). Moreover, it reduces total mortality as well as the need for revascularisations, and delays the start and the progression of congestive heart failu Læs hele dokumentet